BIAL - Registration and Monitoring System for Patients with chronic lymphocitic leukemia

• Autorzy: Ładyżyński P. , Migalska-Musiał K. , Foltyński P. , Kawiak J. , Hus I. , Sieklucka M. , Roliński J. , Dmoszyńska A. , Wójcicki J.M.
• Języki publikacji: EN

Abstrakty

EN

B-cell chronic lymphocitic leukemia (B-CLL) is the most common type of leukemia in adults. The aim of the work was to design and implement a computer registration and monitoring system for patients with B-CLL. The developed BIAL system comprises modules allowing for registration of the data related to patient's identification, patient's general state (e.g. objective examination, phenotype, etc.), laboratory examinations (biochemical, immunological and cytogenetical), applied treatment (chemo- and/or immunotherapy) and evaluation of immunotherapy on an animal model. Selected biochemical and immunological parameters can be presented on charts, to facilitate evaluation of patient's state, the course and outcome of the treatment. The BIAL system was preliminary verified basing on the data registration of 8 B-CLL patients treated with chemo- or immunotherapy in the Clinic of Hematooncology and Bone Marrow Transplantation MU in Lublin. It was found to be comprehensive yet easy to learn and use. The system should facilitate the current treatment of the B-CLL patients and should make a foundation for the future multi-patients data analysis leading to elaboration of the criteria for selection of the optimal treatment regimen for patients with B-CLL.

Słowa kluczowe

EN

chronic lymphocitic leukemia; medical databases; computer systems

PL

przewlekła białaczka limfocytowa; baza danych medycznych; system komputerowy

• Wydawca: Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences ; Elsevier
• Czasopismo: Biocybernetics and Biomedical Engineering
• Rocznik: 2005
• Tom: Vol. 25, no. 3
• Strony: 57--63
• Opis fizyczny: Bibliogr. 8 poz., rys.

Twórcy

autor

Ładyżyński P.

• Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Science,4 Trojdena Street, 02-109 Warsaw, Poland

autor

Migalska-Musiał K.

• Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Science, Warsaw, Poland

autor

Foltyński P.

• Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Science, Warsaw, Poland

autor

Kawiak J.

• Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Science, Warsaw, Poland

autor

Hus I.

• Departament of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland

autor

Sieklucka M.

• Departament of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland

autor

Roliński J.

• Departament of Clinical Immunology, Medical University, Lublin, Poland

autor

Dmoszyńska A.

• Departament of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland

autor

Wójcicki J.M.

• Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Science, Warsaw, Poland

Bibliografia

• [1] Dighiero G., Binet J.L.: When and how to treat chronic lymphocytic leukemia. New Engl. J. Med. 2000, 343, 1799-1801.
• [2] Robak T., Kasznicki M.: Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002, 16, 1015-1027.
• [3] Kawalec M., Skorski T., Kawiak J.: Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclofosfamide and mafosfamide-treated leukemia cells. Invest. New Drugs 1988, 6, 169-172.
• [4] Baars A., Claessen A.M., van den Eertwegh A J., Gall H.E., Stam A.G., Meijer S., Giaccone G., Meijer C.J., Scheper R.J., Wagstaff J., Vermorken J.B., Pinedo H.M.: Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann. of Oncol. 2000, 11, 965-970.
• [5] Vermorken J.B., Claessen A.M., van Tinteren H., Gall H., Ezinga R., Meijer S., Scheper R.J., Meijer C.J.L., Bloemena E.., Ransom J.H., Hanna Jr. M.G., Pinedo H.M.: Active specific immunotherapy for stage II and stage III human colon cancer. A randomised trial. Lancet 1999; 353, 345-350.
• [6] Reid C.D.L.: Dendritic cells and immunotherapy for malignant disease. Brit. J. Haemat. 2001, 112, 874-887.
• [7] Krackhardt A.M., Haring S., Witzens M., Broderick R., Barrett P., Gribben J.G.: T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 2002, 100, 167-173.
• [8] Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternak B.S.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46, 219-234.